Portable heart-lung machine for bedside use
This article was originally published in Start Up
Hemovent GMBH has developed a miniaturized extracorporeal membrane oxygenation system for bedside use in intensive care. The start-up says the footprint of its ECMO is just 10% the size of the smallest commercially available heart-lung machine, and the cost of the unit is 95% less than a standard ECMO device.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.